Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance and Prometheus Expand License, Start Collaboration

NEW YORK, May 16 - Genaissance Pharmaceuticals and Prometheus Laboratories have expanded a licensing agreement and plan to collaborate to identify genetic markers, the companies said today.

 

Prometheus, which licenses a thiopurine S-methyltransferase (TPMT) genetic test from Genaissance, will now be able to use it more broadly. The test assesses a patient's ability to metabolize thiopurine drugs, which are commonly used to treat autoimmune and inflammatory diseases. Genaissance acquired the rights to this test through its purchase of the assets of DNA Sciences.

 

Prometheus paid Genaissance an upfront fee for the license expansion and will make further payments based on net sales.

 

In addition, Genaissance and Prometheus plan to collaborate to identify genetic markers that predict patient responses to therapies used to treat gastrointestinal tract diseases as well as autoimmune and inflammatory diseases. Prometheus focuses on these disease areas.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.